Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

77
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
77
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

81
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
81
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

274
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
274
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

81
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

69
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
69
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.

Research square·2026
Same author

NIH-funded Institutional Training Programs in Colleges and Schools of Pharmacy.

American journal of pharmaceutical education·2026
Same author

Generative AI-assisted Bayesian-frequentist Hybrid Inference in Single-cell RNA Sequencing Analysis for Genes Associated with Alzheimer's Disease.

medRxiv : the preprint server for health sciences·2026
Same author

The Effectiveness of Home-Based Phototherapy in Vitiligo: A Systematic Review and Meta-Analysis.

Photodermatology, photoimmunology & photomedicine·2026
Same author

SCORTEN and Novel Prognostic Markers in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review and Meta-Analysis.

The Australasian journal of dermatology·2026
Same author

Excimer 308-Nm Light in the Combination Treatment of Vitiligo: A Systematic Review and Network Meta-Analysis.

Pigment cell & melanoma research·2026

Related Experiment Video

Updated: Mar 11, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K

Genomic Characterization of Metformin Hepatic Response.

Marcelo R Luizon1,2,3, Walter L Eckalbar1,2, Yao Wang1,2,4

  • 1Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, United States of America.

Plos Genetics
|December 1, 2016
PubMed
Summary

Metformin

More Related Videos

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.2K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.5K

Related Experiment Videos

Last Updated: Mar 11, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.2K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.5K

Area of Science:

  • Genomics
  • Molecular Biology
  • Metabolic Diseases

Background:

  • Metformin is a primary treatment for type 2 diabetes (T2D).
  • Its precise liver mechanisms remain unclear.
  • Understanding these mechanisms is crucial for optimizing T2D therapy.

Purpose of the Study:

  • To systematically map genes and regulatory elements affected by metformin in human liver cells.
  • To distinguish between AMP-activated protein kinase (AMPK)-dependent and -independent pathways.
  • To identify genetic factors influencing individual responses to metformin.

Main Methods:

  • RNA sequencing (RNA-seq) and ChIP sequencing (ChIP-seq) were performed on primary human hepatocytes.
  • Cells were treated with metformin, metformin plus an AMPK inhibitor (Compound C), or vehicle control.
  • Functional validation involved reporter assays, eQTL analysis, and CRISPR activation.

Main Results:

  • Thousands of metformin-responsive genes and regulatory elements were identified, involving both AMPK-dependent and -independent pathways.
  • A novel enhancer regulating ATM, EXPH5, and DDX10 was discovered, linked to metformin response variability.
  • Activating transcription factor 3 (ATF3) was identified as a key metformin-induced AMPK-dependent gene involved in repressing gluconeogenesis.

Conclusions:

  • This study provides a genome-wide view of metformin's hepatic effects.
  • Identified regulatory elements may explain inter-individual differences in glycemic response to metformin.
  • Novel therapeutic targets for T2D and related conditions were uncovered.